Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Q38087930)

28 August 2017

title

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

28 August 2017

main subject

Philadelphia chromosome

1 reference

object named as

Philadelphia chromosome

2 August 2024

A K Fielding

1

1 reference

28 August 2017

G A Zakout

series ordinal

2

1 reference

28 August 2017

publication date

1 June 2013

1 reference

Current hematologic malignancy reports

28 August 2017

published in

1 reference

28 August 2017

volume

8

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

98-108

1 reference

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph ) acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leuk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive acute lymphoblastic leukemia (Ph ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Acute leukemia during pregnancy: a report on 37 patients and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Use of chemotherapy during human pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Imatinib treatment: specific issues related to safety, fertility, and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

21 January 2018

Imatinib in pregnancy.

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Pregnancy on imatinib: fatal outcome with meningocele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-013-0155-4

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

21 January 2018

1 reference

12 December 2020

Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion

1 reference

12 December 2020

Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de

1 reference

12 December 2020

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

1 reference

12 December 2020

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients

1 reference

12 December 2020

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

1 reference

12 December 2020

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

12 December 2020

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).

1 reference

12 December 2020

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

12 December 2020

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

1 reference

12 December 2020

Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia

1 reference

12 December 2020

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

12 December 2020

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

12 December 2020

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

1 reference

12 December 2020

Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance

1 reference

12 December 2020

Treatment of acute leukemia during pregnancy: presentation of nine cases

1 reference

12 December 2020

Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leucocytes

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study

1 reference

12 December 2020

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease

1 reference

12 December 2020

Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Coopera

1 reference

12 December 2020

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

1 reference

12 December 2020

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy

1 reference

12 December 2020

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

12 December 2020

Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

12 December 2020

10.1007/S11899-013-0155-4

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1016555857

0 references

1 reference